Etodolak yüklü poli (Laktid-ko-glikolid) nanopartikülleri: Formülasyon ve i̇n vitro karakter

Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) which blocks the enzyme that makes prostaglandins. NSAIDs treat the symptoms of pain and inflammation. Etodolac is used to treat pain or inflammation caused by arthritis or osteoarthritis. The commonest side effects during therapy are generally gastrointestinal disturbances and nanoparticulate drug delivery systems may reduce these side effects. In this study, nanoparticles were prepared with nanoprecipitation technique. Particle size and zeta potential measurements were performed by Malvern Zetasizer (Malvern Instruments, UK). Mean particle sizes measured were 175 nm and 184 nm for blank and etodolac loaded nanoparticles, respectively and polydispersity indices (PI) were lower than 0.2 for all formulations. Zeta potential values were negative. Examination of photographs of the nanoparticles with Scanning Electron Microscope (Jeol-SEM ASID-10, Japan) revealed that the surface were smooth and spherical. The encapsulation efficiency value of the formulation was found to be 17 %. Nanoparticle formulation showed a significant controlled release profile extended up to 144 h. These results indicated that etodolac-loaded PLGA nanoparticles might provide a promising carrier system for the effective delivery of this anti-inflammatory drug.